Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapies
Presurgical neoadjuvant chemotherapy (NACT) altered the immune microenvironment in patients with stage IIIC/IV tubo-ovarian high-grade serous carcinoma (HGSC), perhaps enhancing the potential...
Source: Ob.Gyn. News - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN | Ovarian Cancer | Ovaries | Serous Carcinoma